|
Jul 20
|
BMO Capital Maintains a Buy on Prime Medicine (PRME), Sets a $10 PT
|
|
Jul 16
|
Cystic Fibrosis Foundation Commits Up to an Additional $24 Million for Prime Medicine to Develop Gene Editing Therapy
|
|
Jul 16
|
Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis
|
|
May 8
|
Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates
|
|
May 8
|
Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates
|
|
Feb 24
|
Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference
|
|
Dec 31
|
Is Prime Medicine (PRME) Among the Top CRISPR Stocks to Invest In?
|
|
Dec 30
|
Why Prime Medicine (PRME) Is One of the Best Biotech Penny Stocks to Invest in Now?
|
|
Oct 16
|
Why I Keep Buying These 14 Incredible Growth Stocks
|
|
Oct 15
|
Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson’s Disease, at Upcoming Scientific Meetings
|
|
Oct 1
|
PRME Stock Rises 11.8% on Collaboration With Bristol Myers
|
|
Oct 1
|
BMS and Prime ink potential $3.5bn deal to develop T cell therapies
|
|
Sep 30
|
Why Prime Medicine Stock Soared Nearly 12% Higher on Monday
|
|
Sep 30
|
Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline
|
|
Sep 30
|
Prime Medicine Unveils Strategically Focused Pipeline
|
|
Sep 30
|
Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies
|
|
Sep 30
|
Prime to narrow gene editing research as it strikes deal with Bristol Myers
|
|
Jun 21
|
Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio
|
|
May 25
|
Here Are the 2 Growth Stocks Google's Parent Company Just Added to Its $7 Billion Portfolio
|
|
May 14
|
Does Prime Medicine, Inc. (PRME) Have the Potential to Rally 133.64% as Wall Street Analysts Expect?
|